To dissect the immunological effects behind the benefits provided by Dexo vaccination, we chose the melanoma-derived protein TRP-2 as a representative antigen to analyze the immune response elicited against B16F10 tumor cells upon Dexo vaccination. The gene discussed is DCT; the disease is neoplasm.